A Next-Generation Plasmid Vector System

NanoplasmidTM Vector System for Genetic Delivery Optimization:

The Power of a Small Backbone for Gene & Cell Therapies

Looking to enhance performance and manufacturing from your DNA backbone, without the regulatory concerns? The small Nanoplasmid backbone fulfills all the requirements. The Nanoplasmid Vector System (<500 bp backbone) provides advantages over existing legacy plasmid DNA backbones and minicircles:

Combining characteristics of reduced size and the RNA-OUT non-antibiotic resistance selection marker, the platform is ideally suited for a range of therapeutic applications. Aldevron can provide customized Nanoplasmid DNA for each client.

Nanoplasmid Benefits by Applications

Application Performance Enhance Manufacturing: (P)lasmid
(E)nd-Product Production
Regulatory Compliant
Increase Transgene Expression Lower Transfection Toxicity
AAV virus1 X X P X
Lentivirus X P/E X
Non-Viral Gene Therapy2 X E X
DNA Vaccines3 X E X
HDR/CRISPR Gene Editing4 X E/P X
Transposons5 X E/P X
mRNA Vector Production P N/A

Have questions? Read our frequently asked questions about Nanoplasmids on our FAQ page.

Nanoplasmid Resources

Nanoplasmid Webinars/Videos

Learn more about Nanoplasmid, view our webinar series here:

Nanoplasmid Brochure & Literature

Scientific Articles

Nanoplasmid is a disruptive technology in the clinical and pre-clinical arena. There have been dozens of publications showing off how this small backbone delivers powerful benefits.

  • Boye C, Arpag S, Burcus N, Lundberg C, DeClemente S, Heller R, Francis M, Bulysheva A. Cardioporation enhances myocardial gene expression in rat heart. Bioelectrochemistry. 2021 Dec;142:107892. doi: 10.1016/j.bioelechem.2021.107892. Epub 2021 Jul 27. PMID: 34371349.

Showing improved electroporation transfection methods in vivo and in vitro using Nanoplasmid versus conventional plasmids for naked DNA expression.

  • Oh SA, Senger K, Madireddi S, Akhmetzyanova I, Ishizuka IE, Tarighat S, et al. High-efficiency nonviral CRISPR/cas9-mediated gene editing of human T cells using plasmid donor DNA. Journal of Experimental Medicine. 2022;219(5).

This publication showed improved CAR-T knock-in efficiency, reduced cell death, and an improved T cell phenotype for CAR-T cell therapies using Nanoplasmid compared to conventional plasmids and linear DNA as an HDR template.

  • Bozza M, De Roia A, Correia MP, Berger A, Tuch A, Schmidt A, et al. A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells. Science Advances. 2021;7(16). doi: 10.1126/sciadv.abf1333

This article discussed how Nanoplasmid was integrated into a rapid and novel manufacturing workflow for the production of CAR-T cell therapies for patients.

For more information on these and other applications, download the complete bibliography.

Nanoplasmid Construct Giveaway
Apply for a Nanoplasmid AAV construct giveaway, and you may be awarded a free plasmid retrofit of your construct into the Nanoplasmid vector system. To apply, submit brief abstract that includes preliminary data and a project proposal. Awards will be granted monthly from March to August. Apply today and discover the Power of Small.

Antibiotic-free selection provided by RNA-OUT

The RNA-OUT platform works by repressing the expression of a counter-selectable marker (SacB) from the host chromosome. SacB encodes for the levansucrase enzyme, which creates a toxic environment in the presence of sucrose, which leads to cell death. Transforming the Antibiotic-free Nanoplasmid in the host expresses a 150bp RNA-OUT antisense RNA (ROUT) that binds the SacB mRNA and represses levansucrase expression, prevents toxicity and to maintain cell survival. The RNA-OUT selectable marker can be used to retrofit existing antibiotic resistance DNA plasmids into antibiotic-free vectors counter-selection system.

ALD Nanoplasmid Bacterial Host Genome_V3_Optimized

Connect with our Specialist

Contact us to schedule a consultation with an expert about your Nanoplasmid product development. In the discussion, our team will evaluate the ability to retrofit your vector into the backbone or design the plasmid within the Nanoplasmid construct for your program.